The Australian influenza drug, GG167, today begins a regulatory and commercial phase which could see the drug, now called Relenza TM, available to the public by next winter. The obstacle course of scientific and clinical development was completed today with application by Biota Holdings Limited for regulatory approval for Relenza's clinical use.
The above story is based on materials provided by CSIRO Australia. Note: Materials may be edited for content and length.
Cite This Page: